- Featured Product
- KD/KO Validated
AKT2 Polyclonal antibody
AKT2 Polyclonal Antibody for WB, IP, IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse, rat
Applications
WB, IP, IHC, ELISA
Conjugate
Unconjugated
Cat no : 17609-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | NIH/3T3 cells |
Positive IP detected in | HepG2 cells |
Positive IHC detected in | human liver tissue, human breast cancer tissue, human liver cancer tissue, human ovary tumor tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:500-1:1000 |
Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
Immunohistochemistry (IHC) | IHC : 1:100-1:400 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
KD/KO | See 2 publications below |
WB | See 13 publications below |
IHC | See 2 publications below |
Product Information
17609-1-AP targets AKT2 in WB, IP, IHC, ELISA applications and shows reactivity with human, mouse, rat samples.
Tested Reactivity | human, mouse, rat |
Cited Reactivity | human, rat, mouse |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | AKT2 fusion protein Ag11770 相同性解析による交差性が予測される生物種 |
Full Name | v-akt murine thymoma viral oncogene homolog 2 |
Calculated molecular weight | 481 aa, 56 kDa |
Observed molecular weight | 56 kDa |
GenBank accession number | BC063421 |
Gene symbol | AKT2 |
Gene ID (NCBI) | 208 |
RRID | AB_2305350 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
AKT2 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis and their activation has been observed in a wide variety of cancers. AKT2 is mainly involved in cancer cell survival, apoptosis inhibition, migration and invasion(PMID:21979951). Defects in AKT2 are a cause of susceptibility to breast cancer (BC). AKT2 promotes metastasis of tumor cells without affecting the latency of tumor development. And defects in AKT2 are a cause of non-insulin-dependent diabetes mellitus (NIDDM) and hypoinsulinemic hypoglycemia with hemihypertrophy (HIHGHH). The full length protein has four glycosylation sites.
Protocols
Product Specific Protocols | |
---|---|
WB protocol for AKT2 antibody 17609-1-AP | Download protocol |
IHC protocol for AKT2 antibody 17609-1-AP | Download protocol |
IP protocol for AKT2 antibody 17609-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
EMBO J Asparagine reinforces mTORC1 signaling to boost thermogenesis and glycolysis in adipose tissues. | ||
Respir Res AKT2 drives cancer progression and is negatively modulated by miR-124 in human lung adenocarcinoma.
| ||
Oncotarget Estrogen regulates miRNA expression: implication of estrogen receptor and miR-124/AKT2 in tumor growth and angiogenesis. | ||
Food Funct l-Theanine regulates glucose, lipid, and protein metabolism via insulin and AMP-activated protein kinase signaling pathways | ||
Front Cell Dev Biol miR-29b-3p Increases Radiosensitivity in Stemness Cancer Cells via Modulating Oncogenes Axis |
Reviews
The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.
FH Tom (Verified Customer) (11-03-2020) | Antibody diluted at 1:500 in blocking solution (5% BSA in TBS) and incubated overnight at 4 degrees.
|